We choose to test the effects of chemerin in the presence of endothelin-1 which has been largely incriminated in the pathogenesis of pulmonary hypertension and is currently therapeutically targeted to treat the disease (Galie et al., 2004, 2019). The gene discussed is RARRES2; the disease is pulmonary hypertension.